The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial
Status:
Terminated
Trial end date:
2020-07-31
Target enrollment:
Participant gender:
Summary
This is a phase IV, multi-center, double-blind, randomized, placebo- controlled study
evaluating the effect of alirocumab on SVG atherosclerotic disease burden, as assessed by
IVUS at baseline and following 78 weeks of treatment in subjects with at least one
intermediate SVG lesion receiving optimal statin therapy. Subjects will be randomized 1:1
into 2 treatment groups: alirocumab 150 mg subcutaneously every 2 weeks or placebo
subcutaneously every 2 weeks.